대동맥판막 치환 시장 보고서 : 수술별, 제품별, 최종 용도별, 지역별(2026-2034년)

The global aortic valve replacement market size reached USD 12.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 27.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.87% during 2026-2034. The increasing prevalence of aortic diseases, rising implementation of health insurance policies, and the growing adoption of MIS procedures represent some of the key factors driving the market.

Aortic valve replacement is a surgical procedure performed to replace a diseased or damaged aortic valve in the heart. It is usually operated through the traditional open-heart surgery, which involves incising the chest or using minimally invasive (MI) methods that require smaller incisions in the chest or a catheter incorporated in the leg. It treats diseases that affect the valves and controls blood flow through the heart. It aids in restoring normal blood flow, reducing symptoms, prolonging life, and preserving the function of the heart muscle. It is generally recommended for patients with severe aortic valve disease, including aortic stenosis or aortic regurgitation, that has symptoms like chest pain, shortness of breath, and fatigue.

AORTIC VALVE REPLACEMENT MARKET TRENDS:

The surging prevalence of aortic diseases among the masses and the increasing aging population that is more prone to developing these medical disorders represent one of the major factors driving the demand for aortic valve replacement around the world. Moreover, the rising implementation of health insurance policies that offer financial assistance for aortic valve replacement and reduce medical expenses is favoring the growth of the market. In addition, the growing awareness about aortic diseases, their symptoms, diagnosis, and the easy availability of the treatment options like aortic valve replacement is influencing the market positively. Apart from this, there is an increase in the adoption of transcatheter aortic valve replacement (TAVR), minimally invasive surgical (MIS) procedure that helps replace the aortic valve without open-heart surgery and is generally preferred by patients who are at major risk for traditional open-heart surgery. This, coupled with the rising preferences for MIS procedures on account of fewer operative complications, shorter hospitalization, less pain, reduced postoperative care, quicker recovery, and lower risk of infection, is propelling the growth of the market. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) in imaging techniques of aortic valve replacement to identify patients who are at higher risk for complications and optimize the procedure and postoperative care is contributing to the market growth. Besides this, governing agencies of numerous countries are undertaking measures to offer quality healthcare facilities that are accessible to all. This, along with significant improvements in the diagnostic technologies, is strengthening the growth of the market.

KEY MARKET SEGMENTATION:

Surgery Insights:

• Open Surgery
• Minimally Invasive Surgery

Product Insights:

• Transcatheter Aortic Valve
• Sutureless Valve
• Others

End Use Insights:

• Hospitals
• Ambulatory Surgery Centers
• Others

Regional Insights:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for aortic valve replacement. Some of the factors driving the North America aortic valve replacement market included extensive research and development (R&D) activities, well established healthcare facilities, integration of advanced technologies, etc.

COMPETITIVE LANDSCAPE:

The report has also provided a comprehensive analysis of the competitive landscape in the global aortic valve replacement market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, Anteris Technologies Ltd., Boston Scientific Corporation, Coroneo Inc., CryoLife Inc., Edward Lifesciences Corporation, JenaValve Technology Inc., LifeNet Health Inc., LivaNova PLC, Medtronic plc, Thubrikar Aortic Valve Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global aortic valve replacement market in 2025?

2. What is the expected growth rate of the global aortic valve replacement market during 2026-2034?

3. What are the key factors driving the global aortic valve replacement market?

4. What has been the impact of COVID-19 on the global aortic valve replacement market?

5. What is the breakup of the global aortic valve replacement market based on the surgery?

6. What is the breakup of the global aortic valve replacement market based on the product?

7. What is the breakup of the global aortic valve replacement market based on the end use?

8. What are the key regions in the global aortic valve replacement market?

9. Who are the key players/companies in the global aortic valve replacement market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Aortic Valve Replacement Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Surgery

• 6.1 Open Surgery
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Minimally Invasive Surgery
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Product

• 7.1 Transcatheter Aortic Valve
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Sutureless Valve
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Ambulatory Surgery Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Anteris Technologies Ltd.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
  • 14.3.3 Boston Scientific Corporation
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Coroneo Inc.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 CryoLife Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Edward Lifesciences Corporation
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 JenaValve Technology Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 LifeNet Health Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 LivaNova PLC
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
  • 14.3.10 Medtronic plc
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Thubrikar Aortic Valve Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio